Saturday 17 October 2026
Export SKYE’s income statement to Excel — free account
Skye Bioscience, Inc.
SKYE Healthcare Biotechnology
In the quarter to June 2026, EPS grew 38.6% and free cash flow grew 34.8%, each against the same quarter a year earlier.
1.55
0.04
−2.52%
Follow SKYE
Skye Bioscience, Inc. (SKYE) P/E ratio
Skye Bioscience, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 18.0× (February 2020) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 18.0×
Ten-year median
0.0×
Current reading's percentile
93
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| SYBX Synlogic, Inc. compare | n/m |
| CLGN CollPlant Biotechnologies Ltd. Sponsored ADR compare | n/m |
| XCUR Exicure, Inc. compare | n/m |
| NIKI Niki BioSolutions, Inc. compare | n/m |
| AIM AIM ImmunoTech Inc. compare | n/m |
| BCLI Brainstorm Cell Therapeutics Inc. compare | n/m |
| FBLG FibroBiologics Inc. compare | n/m |
| SKYE Skye Bioscience, Inc. | n/m |
| CALC CalciMedica Inc. compare | n/m |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)